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GM1 gangliosidosis is a fatal neurodegenerative lysosomal storage disease caused by an autosomal recessively inherited deﬁciency
of β-galactosidase activity. Eﬀective therapies need to be developed to treat the disease. In Shiba Inu dogs, one of the canine GM1
gangliosidosis models, neurological signs of the disease, including ataxia, start at approximately 5 months of age and progress until
the terminal stage at 12 to 15 months of age. In the present study, serial MR images were taken of an aﬀected dog from a model
colony of GM1 gangliosidosis and 4 sporadic clinical cases demonstrating the same mutation in order to characterize the MRI
features of this canine GM1 gangliosidosis. By 2 months of age at the latest and persisting until the terminal stage of the disease,
the MR ﬁndings consistently displayed diﬀuse hyperintensity in the white matter of the entire cerebrum on T2-weighted images.
In addition, brain atrophy manifested at 9 months of age and progressed thereafter. Although a deﬁnitive diagnosis depends on
biochemical and genetic analyses, these MR characteristics could serve as a diagnostic marker in suspect animals with or without
neurological signs. Furthermore, serial changes in MR images could be used as a biomarker to noninvasively monitor the eﬃcacy
of newly developed therapeutic strategies.
1.Introduction
GM1 gangliosidosis is a lysosomal storage disease caused by
autosomal recessively inherited deﬁciency of β-galactosidase
enzyme activity due to the mutations of GLB1 gene [2]. The
major clinical signs are progressive motor and psychointel-
lectual disorders, visual defects, and premature death. At
present, only symptomatic therapy is available, even for hu-
man patients. In animals, GM1 gangliosidosis has been re-
ported in dogs, cats, calves, and sheep. In dogs, the disease
has been detected in mixed-breed beagles [3], English
Springer Spaniels (ESSs) [4], Portuguese water dogs (PWDs)
[5], Alaskan huskies [6], Shiba Inu dogs (SIDs) [7], and a
mixed-breed dog [8]. The molecular defects that cause the
disease have been identiﬁed in PWDs [9], Alaskan huskies
[10], and SIDs [11]. Therefore, these molecularly deﬁned
canine models are expected to provide versatile in vivo sys-
tems for testing newly developed therapeutic strategies such
as gene and regeneration therapies.
The clinical features of GM1 gangliosidosis in SIDs have
b e e nd e s c r i b e di nd e t a i li ns e v e r a lr e p o rt s( Table 1)[ 1, 7, 12–
15]. These clinical features in SIDs are similar to those of
the late infantile/juvenile form (type 2) of human GM1 gan-
gliosidosis [13]. This speciﬁc clinical information makes it2 The Scientiﬁc World Journal
Table 1: Summary of clinical features in Shiba Inu dogs with GM1 gangliosidosis.
Age (months) Clinical features
Birth—5 No speciﬁc neurological signs, but abnormal cytoplasmic vacuoles in 30–50% of lymphocytes are always observed on
blood smears. Ranula of the sublingual salivary gland with unknown etiology may be observed during this period or later.
5-6 Loss of balance; intermittent lameness; mild to moderate ataxia; dysmetria mainly hypermetria; head tremor; intention
tremor.
7-8 Severe ataxia; loss of postural reactions; falling; exaggeratedly startled response to touch and sounds.
9-10 Atactic abasia; astasia; slight corneal clouding; visual disorder; muscle rigospasticity in limbs and crest; slight mental
retardation.
11-12 Generalized muscle spasticity; tonic spasm; tendency to be lethargic; unresponsive to sounds; weight loss.
12–15 Generalized extensive rigor; lethargy; stuporous; death: median age at death is approximately 14 months, but one dog died
at 18 months of age.
Table 2: Dogs and their age in months at the time of MR scanning.
A g e ( m o n t h s ) 234567891 0 1 1
L a b o r a t o r y d o g DDDDDDDDDD
Animal 1 D∗ D∗ D
Animal 2 D∗ DD
Animal 3 D∗
Animal 4 D
C o n t r o l DDDDDDDDDD
D: MR scanning was performed. ∗These MR images were reported previously as prediagnostic data in animals 1 to 3 [1].
possible for veterinary practitioners to more easily recognize
sick dogs demonstrating the signs of GM1 gangliosidosis,
although a deﬁnitive diagnosis depends on the demon-
stration of a deﬁcient enzyme [16] and/or DNA mutation
[11, 17, 18]. Furthermore, the clinical characteristics of this
animalmodelareusefulasamarkerforthedevelopmentand
the testing of potential therapeutic methods for the human
form of the disease [13].
There have been several reports concerning MR images
of human GM1 gangliosidosis [19–24], but only 2 reports
examining MR ﬁndings in canine disease have been pub-
lished [1, 19]. The canine reports describe the discrete MR
features in an ESS and a PWD at 9 months of age [19]
and 3 SIDs at 3–8 months of age [1]. However, serial MR
changes from the preclinical to terminal periods should be
determined in an animal model to establish MR biomarkers
for both the reliable diagnosis and evaluation of the eﬃcacy
of newly developed therapeutic strategies. In the present
study,weperformedserialMRscanningfrom2to11months
ofageinoneaﬀectedSIDfromamodelcolony.Furthermore,
MR scans obtained between 3 and 10 months of age in 4
sporadic clinical cases possessing the same mutation were
also analyzed to conﬁrm the consistency of the serial change
observed in the aﬀected laboratory dog.
2.MaterialsandMethods
2.1. Laboratory Animals. One aﬀected male SID from a pre-
viouslyestablishedJapanesemodelcolony[13]wassubjected
to serial MR scanning from the preclinical to terminal
periods. MR scanning was performed once a month from
2t o1 1m o n t h so fa g e( Table 2). This dog had received a
commercial multivalent vaccine (Duramune MX8, Kyoritsu
Seiyaku, Tokyo, Japan) at 6 and 9 weeks of age. The dog
was isolated in a cage (72cm wide, 124cm long, and 81cm
high) and was allowed to exercise freely outside the cage
for 2-3 hours a day. The room where the cage was placed
was controlled at a temperature of 24–26◦C and humidity
of 40–60%, and the lighting was turned oﬀ during the night-
time for 8–10 hours. The dog was fed commercial dog food
twice per day and allowed to drink water ad libitum while
it was capable of eating and drinking independently, that is,
untilapproximately8monthsofage.Afterthedogdeveloped
abasia and/or astasia, it received nursing care including hand
feedings, infusions, and heat retention. General physical,
neurological, and hematological examinations were carried
out once a month to periodically monitor the clinical status
of the dog. At 11 months of age, the dog was euthanized
humanely by an intravenous injection of pentobarbital
sodium salt (approximately 125mg/kg) due to the poor
prognosis, and necropsy was performed immediately after
the ﬁnal MR scanning had been completed. As an age-
matched control for the aﬀected SID, a normal male Beagle
was obtained from a colony of experimental dogs because
the sizes of the body and cranium are very similar in the
two breeds. This control dog was raised under the same
conditions as the aﬀected dog throughout the experimental
period and underwent monthly MR scanning from 2 to 11
months of age (Table 2) .T h ed o g sw e r ec a r e df o ra n dw e r e
usedintheexperimentsinaccordancewiththeguidelinesfor
proper conduct of animal experiments issued by the Science
Council of Japan [25]. All experimental procedures usingThe Scientiﬁc World Journal 3
experimentalanimalswereperformedinaccordancewiththe
guidelines regulating animal use at the Nippon Veterinary
and Life Science University.
2.2. Clinical Cases. In the present study, MR images of 4
sporadic clinical cases (animals 1 to 4) possessing the same
mutation as the laboratory dog were analyzed to conﬁrm
the consistency of the serial changes observed in the aﬀected
laboratory dog. The homozygous mutation was conﬁrmed
by a DNA test as previously reported [11]. The ages in
months when these clinical cases underwent MR scanning
are shown in Table 2. All animals underwent MR scanning
a few months after the onset of disease (6 to 8 months of
age) as a prediagnostic test prior to the DNA test. Only
animal 1 incidentally underwent MR scanning before the
onset of disease (3 months of age) due to a vertebral prob-
lem unrelated to GM1 gangliosidosis. These diagnostic MR
images of animals 1 to 3 were previously reported [1]. In
animals 1 and 2, MR scanning in the later stages of disease
after the establishment of diagnosis was performed for the
research purposes with owner consent (Table 2). All animals
followed a clinical course similar to that shown in Table 1.
2.3. MR Methods. MR scanning of 2 laboratory dogs was
carried out with a 1.5 Tesla superconducting MR imaging
system (Visart, Toshiba, Tokyo, Japan) using a human knee
coil as a radiofrequency coil under general anesthesia. The
anesthesia was induced by the intravenous injection of
propofol (7.0mg/kg body weight), and then the dogs were
intubated and maintained by the inhalation of isoﬂurane
(1.5–2.0%) and oxygen. The anesthetized dogs were held
in a sternal position on the table with their head in the
radiofrequency coil. During the anesthesia, the heart beat,
temperature, and end-tidal CO2 were monitored, and the
respiration rate (8–12/min) was controlled by a ventilator.
The scanning conditions were T2-weighted (T2W, fast-spin
echo, TR/TE = 4000/100, matrix = 256 × 256, number of
acquisition = 2), with ﬂuid-attenuated inversion recovery
(FLAIR, fast-spin echo, TR/TE/TI = 8000/120/2000, matrix
= 256 × 256, number of acquisitions = 2), and T1-weighted
(T1W, spin echo, TR/TE = 410/15, matrix = 160 × 256,
number of acquisitions = 3) with and without intravenous
gadodiamide contrast agent (0.2mmol/kg, Omniscan, Dai-
ichi, Tokyo, Japan). All images were obtained on a transverse
plane (ﬁeld of view 12 × 12cm, slice thickness 2.5mm, slice
gap 0.5mm) from the olfactory lobe to the caudal medulla
oblongata. MR scanning of animals 1, 2, and 4 was carried
out with a 0.3 Tesla MR imaging system with a permanent
magnet (Airis-II Comfort, Hitachi, Tokyo, Japan) using a
human knee coil as the radiofrequency coil. T2W, FLAIR,
T1W, and gadodiamide contrast-T1W images were obtained
in the transverse plane (slice thickness 3.5–4.0mm, slice
gap 0.5–1.0mm), and some images were obtained in the
sagittal and/or dorsal planes. Animal 3 was scanned with
a 0.5 Tesla permanent magnet MR imaging system (Aperto
Inspire, Hitachi). For MR scanning, these clinical cases were
also anesthetized and monitored by employing almost the
same protocol as that used for laboratory dogs.
2.4. Imaging Analysis. All the obtained images were eval-
uated by 2 veterinary neuroradiologists (D. Hasegawa and
H. Orima), and the ﬁndings were recorded. In the 4 dogs
with serial imaging data (2 laboratory dogs and animals
1 and 2), the regions of interests (ROIs) were produced
along the outline of the brain and ventricular systems, and
the volume of brain parenchyma was measured as the area
(cm2) of each ROI on the transverse FLAIR images from
the ﬁrst image displaying the lateral ventricles to the last
image displaying the 4th ventricle. The area (cm2)o fb r a i n
parenchyma was calculated by subtracting the ROI of the
ventricular system from the ROI of the brain outline and
then multiplying by slice thickness and slice gap to obtain
the volume of brain parenchyma (cm3) in each slice. The
total volume of brain parenchyma (cm3) was calculated by
summing the volume of brain parenchyma in each imaging
series. In addition, the interthalamic adhesion thickness
(mm) that has been reported as an indicator of canine brain
atrophy [26] was measured in each series. Brain volume and
the interthalamic adhesion thickness measurements were
consistently performed by one author (D. Hasegawa) using
the same criterion.
2.5. Histopathology. The brain and other visceral organs
of the aﬀected laboratory dog that was euthanized at 11
months of age were presented for histological investiga-
tion. All organs were evaluated using hematoxylin and
eosin stain. In addition, the brain sample was stained im-
munohistochemically using polyclonal rabbit anti-human
myelin basic protein (MBP) antibody (DakoCytomation,
Glostrup, Denmark) as a primary antibody followed by
a secondary biotinylated goat anti-rabbit IgG antibody
(Vector Laboratories, Burlingame, Calif, USA). Immunore-
activity was detected using a 3,3 -diaminobenzidine sys-
tem (Merck, Darmstadt, Germany) after treatment with
peroxidase-conjugate streptavidin (DakoCytomation). For
this immunohistochemical staining, brain samples were
obtained as a positive control from a 1-year-old Beagle that
died of a cardiac disease and a 2-year-old mixed-breed dog
that died of a bladder rupture.
3. Results
3.1. MR Findings. T2W and FLAIR hyperintensity in the
subcortical white matter of the whole cerebrum was con-
sistently observed on all images of the dogs aﬀected with
GM1 gangliosidosis regardless of timepoint (Figures 1(B),
1(C), and 2). Although this ﬁnding was discovered using
multiple MR imaging systems that ranged from 0.3 to 1.5
Tesla, the images obtained with a 1.5-Tesla system more
clearly demonstrated this abnormal ﬁnding (Figure 1(B)),
while the FLAIR images obtained with a 0.3-Tesla system
were not as clear (Figure 1(C)). In addition, there is an
indication that this ﬁnding became more distinguishable
with progression due to aging regardless of ﬁeld strength
(Figure 2). T2W hyperintensity in the white matter of the
cerebellum was also observed from 7 months of age in the
aﬀected laboratory dog and in animal 1 at 9 months of4 The Scientiﬁc World Journal
Figure 1: Various transverse sections of T2W and FLAIR images at 2 (A: age-matched control dog (control) and B: aﬀected laboratory dog
(model)) or 3 months of age (C: clinical case 1 (animal 1)). T2W hyperintensity in the subcortical white matter of the whole cerebrum was
observed in aﬀected dogs (B, C), but almost nonexistent in the control dog (A). T2W hyperintensity was more clearly recognized in B, which
was obtained by a 1.5 Tesla system, than in C, which was obtained by a 0.3 Tesla system. In addition, subcortical hyperintensity was diﬃcult
to detect on the FLAIR images obtained by a 0.3 Tesla system.
age (Figure 3). However, this cerebellar T2W hyperinten-
sity was not recognized in other clinical cases (data not
shown).
The aﬀected laboratory dog presented symmetrical T1W
hyperintensity and T2W hypointensity in the internal cap-
sule from 2 months of age (Figures 1(B) and 4(b)). Thereaft-
er, this T1W hyperintensity decreased gradually and resolved
at 6 months of age, but the T2W hypointensity in the same
region persisted until 11 months of age (Figure 2). This ﬁnd-
ing was not detected in any images of clinical cases, which
were investigated using a lower ﬁeld strength.
On the serial MR images obtained from 3 dogs, that is,
the aﬀected laboratory dog and animals 1 and 2, ventricular
enlargement and well-demarcated sulci were observed by 8
months of age (Figure 2), suggesting atrophic change.
In the age-matched control dog, mild T2W hyperinten-
sity was observed at the boundary between the cortex and
medulla in the cerebrum, especially the frontal lobe, and
in the margin of the lateral ventricles at 2 months of age
(Figure 1(A)). However, this ﬁnding was almost resolved at
3 months of age and was not visible at all by 4 months of age.
The other abnormal ﬁndings were not observed on either
sequential images or at any timepoint.
3.2. Brain Volumetry and Interthalamic Adhesion Thickness.
The changes in brain volumes in 3 dogs, that is, the aﬀected
laboratorydogandanimals1and2,areshowninFigure 5(a).
In the aﬀected laboratory dog, the brain volume continued
to increase until 8 months of age but started to decrease
at 9 months of age and continued to decrease until the
terminal stage. The interthalamic adhesion thickness, which
is an indicator of canine brain atrophy, changed in the same
way as the transition of the brain volume (Figure 5(b)).
The changes in brain volume and interthalamic adhesion
thickness in animals 1 and 2 were similar to those of
the aﬀected laboratory dog. However, the brain volume of
the age-matched control dog increased rapidly until 3–5
months of age and then remained constant. Changes in the
interthalamic adhesion thickness in this control dog were
similar to those in the brain volume of this dog.
3.3. Histological Findings. At necropsy, gross pathology of
the aﬀected laboratory dog revealed atrophic gyri and
demarcated sulci. Histologically, the neurons were swollen
like balloons throughout the central nervous system and
ﬁ l l e dw i t hs t o r a g em a t e r i a l s( Figure 6(a)). Reactive astro-
cytosis was observed in the neuropil. The developmentThe Scientiﬁc World Journal 5
Figure 2: Serial changes in aﬀected dogs (transverse T2W images at the thalamus/3rd ventricle level). Subcortical T2W hyperintensity was
consistently observed at any timepoint. T2W hypointensity in the internal capsule was also recognized in the aﬀected laboratory animal
(model). Atrophic changes, which were indicated by ventricular enlargement and well-demarcated sulci, were observed in all aﬀected dogs
(model and animals 1–3) from 8 to 9 months of age.
of the white matter appeared poor throughout the cen-
tral nervous system, and vacuolation was found in some
regions. Abnormal myelination, that is, dysmyelination or
demyelination, was detected by a weak reaction to an anti-
MBP antibody (Figure 6(b)) compared with that in positive
control specimens (Figure 6(c)) and that of the subcortical
white matter was more severe than those observed in other
regions.
4. Discussion
The characteristic MR ﬁndings in SIDs with GM1 gangliosi-
dosis were identiﬁed. MR ﬁndings consistently indicated
diﬀuse hyperintensity in the white matter of the entire cere-
brum on T2W images from 2 months of age at the latest and
persisting until the terminal stage. Brain atrophy manifested
at9monthsofageandprogressedthereafter.TheseMRchar-
acteristics could be used as a diagnostic and/or therapeutic
biomarker for this canine GM1 gangliosidosis model.
Human GM1 gangliosidosis is classiﬁed into 3 types:
infantile form (type 1), late infantile/juvenile form (type
2), and adult/chronic form (type 3) [2]. In canine GM1
gangliosidosis, it is thought that the disease in ESSs is similar
to human type 1, while the disease in the other breeds,
including SIDs, is similar to human type 2 [3, 5–7, 27].
Several reports describing MR ﬁndings in these 3 types of
human diseases have been published. Reports describing
types 1 and 2 indicate that symmetrical T2W hypointensity
in the thalamus and diﬀuse T2W hyperintensity in the
cerebral white matter result from delayed myelination [20,
21, 24]. In other reports, abnormal intensity on T2W images
in the basal ganglia is observed in type 3 [28, 29]. To the
best of our knowledge, however, there has been only one
report in the English literature [19] and one report in the
Japanese literature [1] concerning MR ﬁndings in canine
GM1 gangliosidosis. The English report describes diﬀuse
cerebral T2W hyperintensity in one ESS and one PWD at 9
months of age. The Japanese report describes diﬀuse cerebral
T2W hyperintensity as the main ﬁnding in 3 SIDs in the
early stage of the disease using relatively low ﬁeld strength
(0.3–0.5 Tesla). In the present study, we performed serial
MR studies throughout the entire stage in one SID with
GM1 gangliosidosis using higher ﬁeld strength (1.5 Tesla)
and demonstrated some novel ﬁndings that would be useful
for an animal model.
The most signiﬁcant MR ﬁnding of the aﬀected SIDs
was T2W hyperintensity in the white matter of the entire
cerebrum, which was consistently observed from the pre-
clinical (at least 2 months of age) to terminal stages. This
abnormality agrees with observations in human patients6 The Scientiﬁc World Journal
(a) (b)
Figure 3: T2W hyperintensity in the white matter of the cerebellum (transverse image at the 4th ventricle level). (a) An aﬀected laboratory
dog at 9 months of age. (b) Clinical case (animal 1) at 9 months of age.
(a) (b) (c)
Figure 4: Transverse T1W images at the level of the thalamus/3rd ventricle. (a) An age-matched control dog at 2 months of age, (b) an
aﬀected laboratory dog at 2 months of age, (c) clinical case (animal 1) at 3 months of age. Symmetrical T1W hyperintensity was found in
the internal capsule (arrows) in the aﬀected laboratory dog (b), whereas there was no apparent hyperintensity in animal 1 (c). However, this
internal capsule T1W intensity in the aﬀected dog was not higher than that observed in the control dog (a).
with types 1 and 2 of the disease, as well as those aﬀected
ESS and PWD at 9 months of age [19–22, 24]. Although it
remains controversial, the cause of the T2W hyperintensity
in the cerebral white matter has been attributed to primary
hypoplasia of the myelin (hypomyelination) and/or delayed
myelination (dysmyelination) [19, 22, 23, 30, 31] rather
than secondary degeneration (demyelination) resulting from
neuronal death due to the accumulation of storage materials
[24, 32].
In general, T1 and T2 values of the white matter
are shortened by progression of myelination accompanied
by brain development during the infantile period, and
accordingly the white matter becomes hyperintensive on
T1W imaging and hypointensive on T2W imaging [30, 33,
34]. Myelination of the cerebral white matter is completed
by approximately 2-3 years of age in humans. In dogs,
myelination may be completed at 3-4 months of age [35].
In the present study, the age-matched control dog presented
diﬀuse T2W hyperintensity in the boundary between the
gray and white matter of cerebrum, and this ﬁnding was
resolved at 4 months of age. The change suggests that
the myelination in the control dog was completed at
approximately 4 months of age, similar to the literature
reports [35]. This observation provided useful information
to aid the diagnosis of GM1 gangliosidosis in animals
2 and 3, which underwent initial MRI at 6 months of
age. In contrast, the diﬀerentiation between dysmyelination
and infantile incomplete myelination was required in the
aﬀected laboratory dog at 2-3 months of age. However, as
shown in Figure 1, the diﬀerence between dysmyelination
in aﬀected dogs and infantile incomplete myelination in
a normal dog was obvious with respect to hyperintensity
on T2W of the cerebral white matter. Therefore, these
characteristics on MRI, especially T2W hyperintensity in
the cerebral white matter, are a useful tool for antemortem
and/or preclinical diagnoses of gangliosidosis in a suspected
family or breed. However, the possibility of misreading T2W
hyperintensity inthe cerebralwhite matterremains whenthe
images are obtained at lower ﬁeld strengths. In the present
study, it was sometimes diﬃcult to recognize the diﬀuse
T2W hyperintensity on images obtained using the 0.3-Tesla
system.The Scientiﬁc World Journal 7
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Figure 5: Changes in brain volumetry (a) and interthalamic
adhesion thickness (b). Brain volume of the control dog (control)
reached a steady volume at 3–5 months of age, whereas that
of the aﬀected dog (model) increased gradually until 8 months
and then started to decrease. Similar changes were also found in
interthalamic adhesion thickness.
Hyperintensity on T2W of the cerebral white matter is
not only speciﬁc for GM1 gangliosidosis but has also been
foundinotherlysosomalstoragediseasessuchasgloboidcell
leukodystrophy [31, 36] and GM2 gangliosidosis [37–42]i n
humans and animals. In gangliosidoses in domestic animals,
diﬀuse T2W hyperintensity was observed in GM2 gangliosi-
dosis variant 0 (Sandhoﬀ disease) in Japanese domestic cats
[41] and Toy Poodles [42], but not in the same disease in a
Golden Retriever [43]. In canine Sandhoﬀ’s disease in these
two breeds, the nucleus caudatus displayed bilateral T2W
hyperintensity and T1W hypointensity [42, 43], which was
not observed in SIDs with GM1 gangliosidosis in the present
study. In contrast, there are some variations of MR ﬁndings
even within human GM1 gangliosidosis. In a 7-month-old
boy with the infantile form of GM1 gangliosidosis, dots and
stripes with low signal intensity in diﬀuse and symmetrical
T2W hyperintensity were seen in the cerebral white matter
[31].Inan18-month-oldgirlwithGM1gangliosidosis,T1W
imaging presented persistent hyperintensity in the bilateral
thalami, brainstem, and deep cerebellum [21]. In a 14-
month-old girl with the late infantile form of the disease,
MR examination indicated hyperintensity of the thalami
on T1W images, while T2W images indicated decreased
signal intensity of the thalami [20]. The report describing an
adult type of the disease indicates that bilateral symmetrical
putamen hyperintensity on T2W images is observed in more
than 90% of the patients [29]. Therefore, the characteristics
of MR ﬁndings in lysosomal diseases appear to depend on
the molecular basis of the disease, not the mere presence of
the disease itself.
An additional ﬁnding, T2W hyperintensity in the deep
white matter of cerebellum, was found in an aﬀected
laboratory dog and animal 1 in the late stage at 7 months
of age. This ﬁnding was also observed on MR images of
E S Sa n dP W Da t9m o n t h so fa g e ,w h i c hw e r er e c o r d e d
using relatively high ﬁeld strength (1.0 Tesla) [19]. However,
this ﬁnding was not observed clearly in the other animals
in the present study. Therefore, these results suggest that
the existence of increased T2W intensity in the cerebellar
white matter depends on either individual diﬀerences or the
detectionabilityoftheMRimagingsystem.Tothebestofour
knowledge, there has not been any report describing T2W
hyperintensity of the cerebellar white matter in human GM1
gangliosidosis, but T2W hyperintensity has been reported
in humans with Sandhoﬀ’s disease [44]. This change may
result from progression of demyelination, increased storage
materials, and astrocytosis, all of which were observed
histopathologically in the aﬀected laboratory dog.
In the present study, T1W hyperintensity in the bilateral
internal capsule was observed only in the aﬀected laboratory
dog in the early stages of the disease, although this ﬁnding
was not described in the previous study of the aﬀected ESS
and PWD [19]. In human GM1 gangliosidosis, a similar
T1W hyperintensity has been observed in the thalamus,
which is thought to reﬂect developed myelination compared
with the surrounding lesions [21]. Therefore, the T1W hy-
perintensity in the internal capsule seems to be produced
by the progression of normal myelination in this region.
The progression of myelination may exaggerate the T1W
intensity against the surrounding T1W intensity due to de-
layed myelination that is shown as hyperintensity on T2W as
describe above.
Progressive brain atrophy was demonstrated using 2
quantitative methods for serial MR investigation. In human
GM1andGM2gangliosidoses,progressivebrainatrophywas
observedinsomepatientswhounderwentserialMRimaging
studies [21, 39, 40, 44]. Based on data from the aﬀected
laboratory dog and animals 1 and 2, brain atrophy seems to
start at approximately 8-9 months of age and then progresses
untiltheterminalstage.Interestingly,thebrainvolumeofthe
aﬀected dogs had a tendency to increase until approximately
8 months of age, while that of the age-matched control
became constant at 3–5 months of age. These ﬁndings
support the hypothesis that the volume of the gray matter
is increased by the accumulation of storage materials in
the lysosomes of cells until 8 months of age, and then cell
death progresses dramatically resulting in progressive brain
atrophy. In support of this hypothesis, we have reported8 The Scientiﬁc World Journal
(a) (b) (c)
Figure 6: Histological ﬁndings in the aﬀected laboratory dog. (a) High magniﬁcation of hematoxylin and eosin stain. Markedly
swollen neurons ﬁlled with the storage materials were found throughout the central nervous system. Bar = 50μm. (b) Anti-MBP
immunohistochemistry of the cerebrum in an 11-month-old aﬀected dog and (c) a 2-year-old control mixed-breed dog. Poor myelination
was particularly detected in the subcortical white matter in the aﬀected dog compared with that in the control dogs. SCWM: subcortical
white matter, DWH: deep white matter. Bar = 1mm.
previously that MBP in cerebrospinal ﬂuid starts to increase
signiﬁcantly at 9 months of age in aﬀected SIDs [45].
Together with the data from MRI and histopathological
examination in the present study, the increased MBP may
result from the breakdown of axonal myelin caused by the
death of neurons.
Large animal models such as dogs and cats are thought
to be versatile for use in the development of new therapeutic
strategies for human diseases. Canine and feline models
have some disadvantages compared with rodent models;
however, for example, not as many animals can be utilized
for research. If it is possible to noninvasively evaluate the
degree or extent of degeneration in the central nervous sys-
tem using biomarkers obtained from living individuals,
the number of animals necessary to determine the eﬃcacy
of potential therapeutic programs for GM1 gangliosidosis
will be lower concurrently contributing to the welfare of
experimental animals. These ﬁndings on serial MRI may
provide a useful diagnostic and/or therapeutic biomarker for
GM1 gangliosidosis as well as clinical features (Table 1)a n d
previously reported cerebrospinal ﬂuid biomarkers [45].
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